Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.49 -1.04 (-2.09%)
Streaming Delayed Price Updated: 3:13 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
39 40 Next >
News headline image
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants ↗
 
Via Benzinga
News headline image
Why Is Provention Biosciences (PRVB) Stock Up 25% Today? ↗
Provention Biosciences shares are trending after reporting earnings. PRVB stock is also up 25% on hopes of FDA approval for teplizumab. 
Via InvestorPlace
News headline image
Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization From Next Year: Top Stories Tuesday, Nov. 01 ↗
Bloomberg Tesla Migrates Shanghai Factory Workers To Boost US Plant Production 
Via Benzinga
News headline image
Sanofi (SNY) Q3 2022 Earnings Call Transcript ↗
SNY earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost ↗
Sanofi stock jumped Friday after the company reported better-than-expected profit. 
Via Investor's Business Daily
News headline image
Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook ↗
 
Via Benzinga
News headline image
Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech ↗
 
Via Benzinga
News headline image
Sanofi: Q3 Earnings Insights ↗
Sanofi (NASDAQ:SNY) reported its Q3 earnings results on Friday, October 28, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings Sanofi beat estimated earnings by... 
Via Benzinga
News headline image
Earnings Scheduled For October 28, 2022 ↗
Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly earnings at $0.01 per share on revenue of $242.62 million. 
Via Benzinga
News headline image
Sanofi's Earnings Outlook ↗
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an... 
Via Benzinga
News headline image
3 Dividend Stocks That Could Soar 51% to 58%, According to Wall Street ↗
Two of these three pay especially attractive dividends. 
Via The Motley Fool
News headline image
US Stock Futures Lower Following Friday's Rally; Tesla In Focus ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the... 
Via Benzinga
News headline image
New Drugs Approvals Bring No Relief for Ailing Innovent Bio ↗
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
News headline image
2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years ↗
Is now the time to buy Sanofi and Intel? 
Via The Motley Fool
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
News headline image
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product ↗
 
Via Benzinga
News headline image
2 Top Healthcare Stocks to Buy Right Now ↗
Healthcare is about as sticky of a business model as you'll find. 
Via The Motley Fool
News headline image
7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market ↗
Those seeking compelling market ideas during this storm may want to consider these relevant under-$50 stocks to buy. 
Via InvestorPlace
News headline image
2 Stocks Jumping in Thursday's Premarket Trading ↗
Get an early start on the events of the day. 
Via The Motley Fool
News headline image
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate ↗
 
Via Benzinga
News headline image
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
News headline image
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi ↗
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at... 
Via SBWire
News headline image
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer ↗
 
Via Benzinga
News headline image
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗
 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing ↗
 
Via Benzinga
News headline image
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients ↗
 
Via Benzinga
News headline image
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease ↗
 
Via Benzinga
News headline image
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report ↗
 
Via Benzinga
News headline image
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids ↗
 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.